跳至主要内容
临床试验/NCT00163501
NCT00163501已完成3 期

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Clinical Trial to Assess the Long Term Safety of Ciclesonide, Applied as a Nasal Spray (200 Mcg, Once Daily) in the Treatment of Perennial Allergic Rhinitis (PAR) in Patients 12 Years and Older

AstraZeneca42 个研究点 分布在 1 个国家目标入组 600 人开始时间: 2003年12月最近更新:
适应症
相关药物

试验速览

阶段
3 期
状态
已完成
发起方
AstraZeneca
入组人数
600
试验地点
42
主要终点
change in Total Nasal Symptom Scores.

研究概览

简要总结

The purpose of this study is to investigate the safety and effectiveness of ciclesonide nasal spray as compared with placebo (inactive substance) nasal spray in relieving symptoms of perennial allergic rhinitis.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Single Group
主要目的
Treatment
盲法
Double

入排标准

年龄范围
12 Years 至 —(Child, Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • General good health, other than perennial allergic rhinitis
  • History and diagnosis of perennial allergic rhinitis by skin prick test

排除标准

  • Participation in any investigational drug trial within the 30 days preceding the Screening Visit
  • A known hypersensitivity to any corticosteroid or any of the excipients in the formulation
  • Use of any prohibited concomitant medications as defined by the study protocol

结局指标

主要结局

change in Total Nasal Symptom Scores.

次要结局

  • change in symptoms, quality of life, safety.

研究者

发起方
AstraZeneca
申办方类型
Industry
责任方
Sponsor

研究点 (42)

Loading locations...

相似试验